Table 2 Univariate and multivariate analysis of MFS in the entire cohort.

From: Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer

 

Univariate analysis

Multivariate analysis

HR

95% CI

p value

HR

95% CI

p value

Age

> 55 versus ≤ 55

0.77

0.42–1.41

0.396

0.41

0.16–1.05

0.062

T-stage

T2-4 versus T1

5.11

2.78–9.42

 < 0.001

3.31

1.68–6.51

0.001

N-stage

N1 versus N0

4.19

1.97–8.90

 < 0.001

4.04

1.60–10.17

0.003

N2 versus N0

8.83

4.00–19.47

 < 0.001

7.47

2.86–19.54

 < 0.001

Tumor grade

2 versus 1

1.81

0.76–4.31

0.180

1.23

0.49–3.08

0.665

3 versus 1

4.68

1.99–11-02

 < 0.001

2.03

0.75–5.48

0.164

ER status*

Pos versus neg

0.41

0.22–0.79

0.007

0.26

0.04–1.59

0.146

PR status*

Pos versus neg

0.55

0.30–0.99

0.047

0.53

0.18–1.56

0.249

HER2 status*

Pos versus neg

2.07

1.00–4.28

0.051

1.37

0.48–3.91

0.558

TN status

Yes versus no

1.92

0.93–3.97

0.080

0.60

0.13–2.99

0.530

mGluR1

Pos versus neg

1.65

0.89–3.04

0.111

   

Chemotherapy

Yes versus no

1.75

0.98–3.13

0.058

0.22

0.08–0.59

0.003

Hormonal therapy

Yes versus no

1.88

1.04–3.38

0.036

1.86

0.58–5.97

0.297

  1. *As retrieved from TMA.
  2. mGluR1 was not added in the multivariate base model with known prognostic markers because no significance was achieved in univariate regression analysis.
Back to article page